Queen Mary University of London: New Combination Treatment Could Extend the Lifetime of People With Amyotrophic Lateral Sclerosis (ALS)
May 15, 2025
May 15, 2025
LONDON, England, May 15 -- Queen Mary University of London issued the following news:
* * *
New combination treatment could extend the lifetime of people with amyotrophic lateral sclerosis (ALS)
The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment for this degenerative disorder slowed functional decline and extended the lifespan of people with ALS.
ALS (also known as Motor . . .
* * *
New combination treatment could extend the lifetime of people with amyotrophic lateral sclerosis (ALS)
The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment for this degenerative disorder slowed functional decline and extended the lifespan of people with ALS.
ALS (also known as Motor . . .